AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ENGN · NASDAQ · Biotechnology

enGene Therapeutics

Develops non-viral genetic medicines led by a bladder-cancer therapy candidate.

$1.83

After-hours close+0.00 (+0.08%)

At close$1.83(−4.19%)

Something off on this page? Send us feedback.

Profile

enGene Holdings Inc.ENGNHealth Care

Develops genetic medicines using the DDX delivery platform, with detalimogene voraplasmid as its lead bladder-cancer program. The clinical-stage company concentrates on localized, non-viral delivery of gene cargos to mucosal tissues and other organs.

Builds genetic medicines around its proprietary Dually Derivatized Oligochitosan (DDX) platform, which is designed for localized, non-viral delivery of multiple gene cargos to mucosal tissues and other organs. Detalimogene voraplasmid, formerly EG-70, is the lead investigational intravesical non-viral gene therapy in study for high-risk non-muscle-invasive bladder cancer.

Operates as a clinical-stage biotechnology company based in Montreal, Quebec, with its Nasdaq listing originating from a 2023 SPAC business combination. The operating business dates to 1999, predating the issuer's short public-company history. Development progress depends on the LEGEND study evaluating detalimogene across high-risk NMIBC cohorts.

Company facts

CEORon Cooper

ListedNov 1, 2023

ExchangeNASDAQ

HeadquartersMontreal, Canada

CountryCanada

Employees82

CIK0001980845

ISINCA29286X1015

Key statistics

Market cap$122.3M

EPS (ttm)−$1.32

P/E (ttm)−1.39

ROE-29.3%

P/B0.4987

P/S0.00

Dividend yield—

Beta2.22vs XLV 0.91

Year to date −79.3% · Average volume (30d) 701.1K

Analysts

Price target, next 12 months$3.00+63.9%Median of 9 analysts · vs the Aug 28 close

ConsensusHold3 of 9 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $1.83

High$4.00+118.6%

Median$3.00+63.9%

Low$2.00+9.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jun 18, 2026	Morgan Stanley	Downgrade	Equal Weight	Underweight		$3
Jun 16, 2026	H.C. Wainwright	Target			$25	$4
May 14, 2026	UBS	Reiterate		Neutral	$10	$2
May 8, 2026	Leerink Partners	Target			$17	$2
May 8, 2026	Raymond James	Target			$27	$4

Earnings

EPS

Estimate−$0.47

ReportedDue Sep 14, 2026

Revenue

Estimate—

ReportedDue Sep 14, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jun 15, 2026Q2 FY26	−$0.48	−$0.43	+10.4%	—	—	—	−1.13%
Jun 11, 2026Q2 FY26	−$0.48	−$0.43	+10.4%	—	—	—	−1.22%
Mar 9, 2026Q1 FY26	−$0.55	−$0.44	+20.0%	—	—	—	−1.56%
Dec 22, 2025Q4 FY25	−$0.57	−$0.73	−28.8%	—	—	—	+5.13%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	$0	$0	$0	−$189.0K	−$180.0K
Operating income	−$26.6M	−$27.1M	−$29.9M	−$39.5M	−$31.2M	$32.0M
Net income	−$24.6M	−$25.8M	−$29.0M	−$37.9M	−$29.8M	$30.2M
Diluted EPS	−$0.48	−$0.51	−$0.57	−$0.74	−$0.44	$0.43
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Apr 30, 2026Cash & short-term investments $258.5M · Total debt $33.4M · Total assets $307.5M · Shareholders' equity $255.2M

Dividends

No dividends on record.

Ownership

Institutions 74.29%49.76M sharesInsiders 0.05%34.4K sharesOther 25.66%17.19M shares

Shares outstanding 66.99M · Float 24.51M · 36.6% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
FCPM Iii Services B.V.	9.63M	14.38%	13F	Aug 14, 2026
BML Capital Management, LLC	6.67M	9.96%	13F	Aug 7, 2026
BML Investment Partners, L.P.	6.67M	9.95%	13G	May 14, 2026
Siren, L.L.C.	6.26M	9.34%	13F	Aug 13, 2026
Perceptive Advisors LLC	4.82M	7.20%	13F	Aug 14, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.